Pharmacological targeting the ATR–CHK1–WEE1 axis involves balancing cell growth stimulation and apoptosis

Joyce P.Y. Mak¹, Wing Yu Man¹, Hoi Tang Ma¹ and Randy Y.C. Poon¹

¹ Division of Life Science, Center for Cancer Research, and State Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong

Correspondence to: Randy Y.C. Poon, email: rycpoon@ust.hk

Keywords: anticancer drugs; checkpoint; DNA damage; mitosis; mitotic catastrophe

Received: June 14, 2014  Accepted: September 24, 2014  Published: September 25, 2014

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The ATR–CHK1–WEE1 kinase cascade’s functions in the DNA damage checkpoints are well established. Moreover, its roles in the unperturbed cell cycle are also increasingly being recognized. In this connection, a number of small-molecule inhibitors of ATR, CHK1, and WEE1 are being evaluated in clinical trials. Understanding precisely how cells respond to different concentrations of inhibitors is therefore of paramount importance and has broad clinical implications. Here we present evidence that in the absence of DNA damage, pharmacological inactivation of ATR was less effective in inducing mitotic catastrophe than inhibition of WEE1 and CHK1. Small-molecule inhibitors of CHK1 (AZD7762) or WEE1 (MK-1775) induced mitotic catastrophe, as characterized by dephosphorylation of CDK1 Tyr15, phosphorylation of histone H3 Ser10, and apoptosis. Unexpectedly, partial inhibition of WEE1 and CHK1 had the opposite effect of accelerating the cell cycle without inducing apoptosis, thereby increasing the overall cell proliferation. This was also corroborated by the finding that cell proliferation was enhanced by kinase-inactive versions of WEE1. We demonstrated that these potential limitations of the inhibitors could be overcome by targeting more than one component of the ATR–CHK1–WEE1 simultaneously. These observations reveal insights into the complex responses to pharmacological inactivation of the ATR–CHK1–WEE1 axis.

INTRODUCTION

Cyclin-dependent kinase 1 (CDK1) is the major kinase for driving cells into mitosis. A defining characteristic of CDK1 activation is a system of feedback loops that converts the progressive accumulation of its activating partner cyclin B1 into an abrupt activation of CDK1 [1]. Premature activation of cyclin B1–CDK1 complexes is prevented by a mechanism involving inhibitory phosphorylation of CDK1 Thr14/Tyr15 by MYT1 and WEE1. At the end of G₂, the stockpile of inactive cyclin B1–CDK1 complexes is rapidly activated by CDC25 phosphatases. Cyclin B1–CDK1 catalyzes its own activation with feedback loops that activate CDC25 and inactivate WEE1/MYT1.

WEE1 is a dual-specificity kinase that phosphorylates CDK1 Thr15 (but not CDK1 Thr14) [2]. MYT1, a kinase that normally bound to the endoplasmic reticulum and Golgi complex, can phosphorylate both the Thr14 and Tyr15 [3,4]. While WEE1 plays an indispensable role in controlling the timing of mitosis, MYT1 appears to play a relatively minor role in the somatic cell cycle [5].

A surveillance mechanism termed the G₂ DNA damage checkpoint prevents entry into mitosis after DNA damage. The checkpoint comprises of a kinase cascade initiating with the activation of ATM and the related ATR. Activated ATM/ATR then phosphorylates residues in the SQ/TQ domain of CHK1 and CHK2, stimulating the activity of these effector kinases [6]. CHK1/CHK2 subsequently acts on all three isoforms of the CDC25 family to suppress their activities [1]. CHK1 also phosphorylates and activates WEE1 by promoting 14-3-3 binding [7,8]. Suppression of CDC25 or activation of WEE1 tips the balance towards CDK1 Thr14/Tyr15 phosphorylation, thereby preventing damaged cells from entering mitosis. Although there are considerable...
overlaps in the ATM/ATR–CHK1/CHK2 axis, it is generally believed that while the ATM–CHK2 pathway primarily responds to DNA double-strand breaks, the ATR–CHK1 pathway is activated by a broader spectrum of DNA abnormalities [9]. Premature inactivation of the checkpoint promotes a process often termed mitotic catastrophe, which is characterized by precocious mitosis followed by apoptosis or mitotic slippage [10].

Agents that cause replication stress also activate a similar checkpoint involving ATR–CHK1–WEE1. ATR is activated after recruited to the single-strand binding protein RPA that coats ssDNA, thereby stabilizing the stalled forks and initiating checkpoint activation [11]. Origin firing, replication forks progression, and mitosis are suppressed by this checkpoint.

In addition to its role in checkpoint control, the ATR–CHK1–WEE1 pathway also plays an essential role in the unperturbed cell cycle. Deletion of ATR [12,13], CHK1 [14], or WEE1 [15] resulted in embryonic lethality. Inhibition of these kinases during normal S phase facilitates an unscheduled activation of cyclin E–CDK2. The resulting increase in initiation of DNA replication promotes DNA damage in a yet incompletely understood mechanism [16]. One possibility is that the unscheduled initiation of dormant origins reduces cellular resources such as dNTPs or histone chaperones to levels insufficient to support the number of active replication forks, thereby leading to replication stalling and SLX4/MUS81-mediated DNA double-strand breakage [17][18].

A promising anticancer strategy is by ablating the G1, DNA damage checkpoint through targeting the ATR–CHK1–WEE1 pathway. A number of small-molecule inhibitors of ATR, CHK1, and WEE1 are being evaluated in clinical trials, mainly in combination with DNA-damaging agents. On the other hand, it is possible that these inhibitors can be effective as monotherapeutic agents without DNA damage. Establishing precisely how cells respond to different concentrations of inhibitors is therefore of crucial importance. Based on these premises, we found that in the absence of DNA damage, inhibition of ATR was less useful in inducing mitotic catastrophe compared to inhibition of WEE1 and CHK1. Unexpectedly, sublethal concentrations of inhibitors of WEE1 and CHK1 in fact accelerated the cell cycle and increased cell proliferation. We demonstrated that combinatorial treatment of inhibitors targeting the ATR–CHK1–WEE1 pathway may be an alternative and effective strategy in inducing mitotic catastrophe without using DNA damage.

RESULTS

Pharmacological inactivation of CHK1 and WEE1 but not ATR induces mitotic catastrophe

Given that relatively specific small-molecule inhibitors of components of the ATR–CHK1–WEE1 cascade have been developed, we first examined if they could stimulate similar cell cycle responses in otherwise unstressed cells. Fig 1A shows that incubation of HeLa cells with the WEE1 inhibitor MK-1775 [19] (designated WEE1i herein) or the CHK1 inhibitor AZD7762 [20] (designated CHK1i herein) was sufficient to enrich cells in G2/M or the later part of S phase. The appearance of cells possessing sub-G1 DNA content after incubation with high concentrations of the chemicals indicated extensive apoptosis was induced (Fig 1A).

In marked contrast, an inhibitor of ATR (VE-821 [21], designated ATRi herein) did not induce similar cell cycle delay even when used at 10 µM (250 nM of CHK1i or WEE1i was sufficient to induce G2/M defects) (Fig 1A). Similar results were obtained using another cell line (H1299) (Supplemental Fig S1A), excluding the possibility that the differential effects of the chemicals were peculiar for HeLa cells.

Inhibition of either CHK1 or WEE1 resulted in mitotic catastrophe, as indicated by the dephosphorylation of CDK1 Tyr15 and an accumulation of mitotic markers including phosphorylated histone H3Ser10 (Fig 1B and 1C). The cells eventually accumulated DNA damage and underwent apoptosis, as indicated by the appearance of γ-H2AX and cleaved PARP1, respectively. As expected, ATRi did not affect these mitotic and apoptotic events up to 5 µM (Fig S1B).

To attain more direct insights into the fates of CHK1i/WEE1i-treated cells, cells expressing histone H2B-GFP were used and individual cells were tracked with live-cell imaging. Time-lapse microscopy indicated that inhibition of WEE1 (and to a lesser extent CHK1) increased the duration of mitosis (Fig 1D, the data for 1C). The cells eventually accumulated DNA damage and underwent apoptosis, as indicated by the appearance of γ-H2AX and cleaved PARP1, respectively. As expected, ATRi did not affect these mitotic and apoptotic events up to 5 µM (Fig S1B).

To ensure that the ATRi used was actually capable of inhibiting ATR, cells were first arrested in G1 phase with DNA damage before challenged with ATRi (Fig 2A). Activation of the G1 DNA damage checkpoint by ionizing radiation was characterized by a high level of CDK1 Tyr15 phosphorylation and a low level of histone H3Ser10 phosphorylation. Significantly, 2.5 µM of ATRi was sufficient to overcome the checkpoint, reversing the phosphorylation of CDK1 Tyr15 and histone H3Ser10. We also tracked the fate of the ATRi-treated cells directly using time-lapse microscopy. Fig 2B shows that while control
cells entered and exited mitosis randomly during the imaging period, the majority of cells stopped cell cycle progression and remained in interphase after IR was applied. Significantly, the IR-treated cells were able to enter mitosis in the presence of ATRi, indicating that the G2 DNA damage checkpoint was abrogated. As expected, checkpoint abrogation resulted in mitosis that was longer than normal and with frequent mitotic slippage. As a control and in accordance with the above data, incubating the cells with the same concentration of ATRi alone did not affect the unperturbed mitosis (the slight extension of mitosis compare to control was not significant; P > 0.1).

Taken together, these results revealed fundamental differences among the current generations of chemicals that target components of the ATR–CHK1–WEE1 kinase cascade: while mitotic catastrophe is induced by targeting either CHK1 or WEE1, unstressed cells are relatively unresponsive to ATR inhibition.

Figure 1: Differential effects of targeting components of the ATR–CHK1–WEE1 cascade. (A) Inhibition of CHK1, WEE1, but not ATR disrupts the cell cycle. HeLa cells were incubated with either buffer or the indicated concentrations of MK-1775 (WEE1i), AZD7762 (CHK1i), or VE-821 (ATRi). After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N and 4N DNA content are indicated. Note that a higher range of ATRi concentration was used. (B) WEE1i induces premature mitosis and apoptosis. HeLa cells were incubated with either buffer or different concentrations of WEE1i as described in panel (A). Lysates were prepared and the expression of the indicated proteins was analyzed with immunoblotting. Actin analysis was included to assess protein loading and transfer. (C) CHK1i induces premature mitosis and apoptosis. HeLa cells were treated with either buffer or different concentrations of CHK1i as described in panel (A). Lysates were prepared and the expression of the indicated proteins was analyzed with immunoblotting. (D) Inhibition of CHK1 and WEE1 increases mitotic duration. HeLa cells expressing histone H2B-GFP were incubated with CHK1i or WEE1i (100 nM or 1 µM). Individual cells were then tracked for 24 h using time-lapse microscopy. The mitotic duration was quantified (mean ±90% CI; n = 50). Treatment with 1 µM of CHK1i or WEE1i significantly increased mitotic length (*** P < 0.001, ** P < 0.01; Student’s t-test). The detailed data for individual cells are shown in Fig S2. (E) Inhibition of CHK1 and WEE1 reduces survival. Cells were treated with CHK1i or WEE1i and imaged with time-lapse microscopy as described in panel (D). The percentage of cell survival was quantified (n = 50). Mean ±SD was calculated from three independent experiments. Treatment with 1 µM of CHK1i or WEE1i significantly reduced survival (** P < 0.01; Student’s t-test).
Partial inhibition of WEE1 and CHK1 has the unexpected effect of promoting cell proliferation

To determine the effects of different concentrations of WEE1i/CHK1i on cell proliferation, we initially analyzed a cell line (HONE1) expressing the infrared fluorescent protein iRFP. We used the recently devised iRFP-based platform to measure cell proliferation because of its broad linear range, high sensitivity, and the capability in providing rapid and economical time-dependent measurement of the effects of drugs on cell growth [22]. As anticipated, high concentrations of WEE1i and CHK1i inhibited cell proliferation (Fig 3A). We noted, however, that cell growth was slightly increased at lower concentrations of WEE1i. This growth simulation was also observed when the cell cycle of individual cells was analyzed using time-lapse microscopy (Fig 3B). When WEE1i was applied to a randomly growing population, the first mitosis in general occurred earlier than in the control cells. More WEE1i-treated cells were also able to undergo

Figure 2: Disruption of the G2 DNA damage checkpoint by ATRi. (A) Disruption of the DNA damage checkpoint by VE-821. HeLa cells were either untreated or irradiated with 15 Gy of ionizing radiation (IR). After 16 h, the cells were incubated with either buffer or 2.5 µM of VE-821 (ATRi). Nocodazole was also applied to trap cells in mitosis. The cells were harvested after another 6 h. Lysates were prepared and the indicated proteins were detected with immunoblotting. Uniform loading of lysates was confirmed by immunoblotting for actin. (B) Inhibition of ATR bypasses the IR-mediated G2 arrest. HeLa cells expressing histone H2B-GFP were either untreated or irradiated with 15 Gy of IR. After 16 h, the cells were incubated with either buffer or ATRi (2.5 µM). Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n = 50). Grey: interphase; black: mitosis (from DNA condensation to anaphase); truncated bars: cell death. ATRi-treated cells entered the first mitosis significantly faster (*** P < 0.001; Student’s t-test) and more cells were able to undergo the second mitosis during the imaging period. (C) Cells were treated with IR and ATRi and analyzed with live-cell imaging as described in panel (B). The percentages of cells that entered mitosis and survival during the imaging period were quantified (n = 50). Mean ±SD was calculated from three independent experiments. Treatment with ATRi significantly promoted mitosis (*** P < 0.001) and reduced survival (* P < 0.1) in IR-treated cells (Student’s t-test).
a second mitosis during the imaging period.

A similar increase in cell proliferation after incubation with low concentrations of WEE1i was also observed with other cell lines, including H1299 (Fig S3A) and HeLa (Fig S3B). In some cell lines, an increase in cell growth was also observed with low concentrations of CHK1i (Fig S3A and S3B). We also verified the increase of cell number using conventional trypan blue staining and cell counting (Fig S3C).

Although ATRi alone did not trigger mitotic catastrophe in HeLa cells, it also accelerated the cell cycle (Fig 2B). ATRi-treated cells entered the first mitosis significantly faster (\(P < 0.01\); Student’s \(t\)-test) and more cells were able to undergo the second mitosis during the imaging period.

To further test the idea that partial inhibition of WEE1 could increase cell growth, we generated cell lines stably expressing a kinase-inactive version of WEE1 (K328R) (Fig S4B). A N\(\Delta\)214 truncation version lacking the negative regulatory domain of WEE1 was also used (see Fig S4A for a schematic diagram of the constructs). Fig 4 shows that both kinase-inactive WEE1\(^{K328R}\) and WEE1\(^{\Delta214(KR)}\) speeded up proliferation, reducing the doubling time by over 20%. Although the proportion of

Figure 3: Partial inhibition of WEE1 accelerates the cell cycle. (A) Low concentrations of WEE1i stimulates cell growth. HONE1 expressing iRFP (~200 cells) were seeded onto 6-well culture plates and cultured in the presence of buffer or the indicated concentrations of WEE1i or CHK1i (diluted with buffer). After 24 h, the cells were washed gently and propagated in normal medium. The plate was scanned daily with an Odyssey infrared imaging system and the iRFP signal was quantified. Dilution of DMSO alone did not affect cell growth (data not shown). (B) Acceleration of the cell cycle by a low concentration of WEE1i. HONE1 cells expressing histone H2B-GFP were incubated with either buffer or WEE1i (100 nM). Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (\(n = 50\)). Grey: interphase; black: mitosis (from DNA condensation to anaphase); truncated bars: cell death. The second mitosis represents that of one of the daughter cells from the first mitosis. The time of entry into the first mitosis was quantified (mean ±90% CI; \(n = 50\)). WEE1i significantly shortened the time for entering mitosis (\(* * P < 0.01\); Student’s \(t\)-test).
different cell cycle phases was not significantly affected by kinase-dead WEE1(KR) (Fig S4C), the cell cycle as a whole was shortened (Fig S4D). By contrast, expression of the corresponding kinase-active WEE1 and WEE1(N214) reduced cell proliferation (Fig 4) and slowed down the cell cycle (Fig S4D). Taken together, these results indicated that while complete inhibition of WEE1 inhibited cell growth, limited inhibition of the ATR-CHK1-WEE1 pathway, either with relative low concentrations of inhibitors or kinase-inactive mutants of WEE1, could accelerate the cell cycle and stimulate growth.

Targeting CHK1 and WEE1 together enhances mitotic catastrophe

A general approach for target therapies is to utilize minimum drug doses to reduce non-specific effects and general toxicity. However, as depicted above, limited inhibition of WEE1/CHK1 has the potential of actually stimulating cell proliferation. As ATR, CHK1, and WEE1 are components of a linear pathway, we next tested if more extensive mitotic catastrophe can be induced when more than one component are targeted together, even with relatively low concentrations of the drugs.

Interestingly, although ATRi alone did not affect the cell cycle (Fig 1A, S1A, and 2B), it was able to enhance premature mitosis when combined with sublethal concentrations of CHK1i or WEE1i. Incubating cells with ATRi and CHK1i or ATRi and WEE1i induced a higher portion of G2/M cells than the individual chemicals alone (Fig 5A). Consistent with mitotic catastrophe, cells receiving both chemicals expressed dephosphorylated CDK1 Tyr15, phosphorylated histone H3 Ser10, and cleaved PARP1 (Fig 5B).

By comparison, combining CHK1i and WEE1i promoted massive cell death (Fig 6A). Again, sublethal concentrations of CHK1i and WEE1i which did not trigger mitotic catastrophe on their own were used here. The combined treatments prompted dephosphorylation

Figure 4: Kinase-inactive WEE1 accelerates the cell cycle. The parental H1299 and H1299 expressing WEE1, N214, WEE1(KR), and N214(KR) were plated at a low density. The number of cells were counted at different time points (average ±SD of three independent experiments). The population doubling time was estimated by plotting the log of cell number against time (lower panel).

|             | Doubling time (h±SD) | Change relative to control |
|-------------|----------------------|-----------------------------|
| WEE1(KR)    | 17.6 ± 0.19          | -24%                        |
| N214(KR)    | 16.7 ± 1.81          | -28%                        |
| Control     | 23.3 ± 1.64          | 0%                          |
| N214        | 27.7 ± 0.78          | 19%                         |
| WEE1        | 27.3 ± 0.61          | 17%                         |

Figure 5: ATRi cooperates with CHK1i/WEE1i in promoting mitotic catastrophe. (A) Targeting ATR and CHK1/WEE1 together increases the G2/M population. HeLa cells were incubated with different combinations of ATRi (2.5 µM), CHK1i (62.5 nM), and WEE1i (125 nM). After 24 h, the cells were harvested and analyzed with flow cytometry. (B) Targeting ATR and CHK1/WEE1 together promotes mitotic catastrophe. Cells were treated as described in panel (A). Lysates were prepared and the indicated proteins were detected with immunoblotting.
of CDK1<sup>Tyr15</sup>, phosphorylation of histone H3<sup>Ser10</sup>, and accumulation of γ-H2AX (Fig 6B). Consistent with apoptosis, there was an increase in PAPR1 cleavage and cell death (Fig 6B). Time-lapse microscopy confirmed that CHK1i and WEE1i together induced a prolonged mitosis and extensive cell death compare to the individual chemicals alone (Fig 6C).

To address if the effects of CHK1i and WEE1i were specific for the respective kinases, CHK1 and WEE1 were also downregulated with siRNAs. Fig 7A verifies that downregulation of CHK1 with siRNA increased the sensitivity to WEE1i (Fig 7A). Conversely, siRNA against WEE1 enhanced the disruption of the cell cycle by CHK1i. Not surprisingly, knockdown of CHK1 or WEE1 enhanced the effectiveness of CHK1i or WEE1i, respectively. Immunoblotting analysis confirmed the downregulation of CHK1 and WEE1 (Fig 7B). It also revealed the increase in premature mitosis (histone H3<sup>Ser10</sup> phosphorylation) and apoptosis (PARP1 cleavage) by the combination of siRNAs and inhibitors.

Figure 6: CHK1i cooperates with WEE1i in promoting mitotic catastrophe. (A) Combining CHK1i and WEE1i induces extensive cell cycle disruption. HeLa cells were exposed to the indicated concentrations of CHK1i and WEE1i individually or in combination. After 24 h, the cells were harvested and analyzed with flow cytometry. (B) Combining CHK1i and WEE1i induces mitotic catastrophe. Cells were treated as described in panel (A). Lysates were prepared and analyzed with immunoblotting. Uniform loading of lysates was confirmed by immunoblotting for actin. The cells were also harvested for trypan blue exclusion assay (bottom panel, average ±SD of triplicated counting). Combination of CHK1i and WEE1i reduced viability (*** P < 0.001; * P < 0.01; Student’s t-test). (C) Coinhibition of CHK1 and WEE1 promotes extensive mitotic delay and cell death. HeLa cells expressing histone H2B-GFP were incubated with CHK1i (100 nM) or WEE1i (100 nM) individually or in combination. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n = 50). Grey: interphase; black: mitosis (from DNA condensation to anaphase); truncated bars: cell death. The mitotic duration was quantified (mean ±90% CI) (*** P < 0.001; Student’s t-test).
Collectively, these data indicated that even with sublethal concentrations of inhibitors, targeting ATR with either CHK1 or WEE1, or CHK1 and WEE1 concurrently induced massive mitotic catastrophe.

**DISCUSSION**

A major focus of the clinical development of inhibitors of the ATR–CHK1–WEE1 pathway is for combination with chemo- and radiotherapy. For example, ATRi (VE-821) was found to enhance the cytotoxicity caused by DNA damaging agents, particularly in cells with defective ATM and p53 [23]. Likewise, several studies have detailed the properties of inhibitors of CHK1 [24] and WEE1 [25] on sensitizing cells to DNA damage.

As standalone agents, CHK1i and WEE1i are believed to induce DNA damage by unscheduled initiation of DNA replication [16][18]. Given that CHK1 and WEE1 are components of the checkpoint itself, the DNA damage induced by CHK1i/WEE1i is unable to elicit an effective checkpoint response. Hence inhibition of CHK1i/WEE1i is expected to disrupt cells in a two-step process. DNA damage is first induced by the unscheduled initiation of DNA replication during S phase, which normally would turn on the G2 DNA damage checkpoint. The presence of CHK1i/WEE1i, however, uncoupled the checkpoint and allowed the damaged cells to enter mitosis. It should be noted that the cell lines used in this study have defective p53 responses (HeLa: p53 is degraded by HPV E6; H1299: p53 genes are deleted), a feature commonly found in many cancers. The lack of p53-dependent cell cycle arrest should further enhance both the precocious S phase progression and mitotic entry induced by CHK1i and WEE1i.

In agreement with the above hypothesis, CHK1i and WEE1i induced an accumulation of G2/M cells in HeLa (Fig 1A) and H1299 (Fig S1A). Several lines of evidence verified that CHK1i and WEE1i triggered mitotic catastrophe, including the increase of histone H3\(^{\text{Ser10}}\) phosphorylation, apoptosis (Fig 1B and 1C), and an extension of mitotic duration (Fig 1D). Not surprisingly, exposure to CHK1i/WEE1i eventually led to a decline of viability (Fig 3A and S3), probably mainly due to mitotic cell death (Fig 1D and 1E).

By comparing inhibitors targeting ATR, CHK1, and WEE1 side-by-side on the same cell lines, we found that in contrast to CHK1i and WEE1i, ATRi was relatively ineffective in inducing mitotic catastrophe (Fig 1A). These findings were confirmed more rigorously by tracking individual cells using live-cell imaging (Fig 2B and S2). Moreover, the relative ineffectiveness of ATRi was not limited to HeLa cells (Fig 1A), but also displayed by H1299 (Fig S1A), as well as several cell lines from nasopharyngeal carcinoma we tested (our unpublished data). Given that the K\(_i\) of the ATRi VE-821 is 6 nM (and >600-fold selectivity over related kinases ATM or DNA-PK) [21], the concentrations of ATRi used in this study should be sufficient to inhibit the kinase. Indeed, the IR-induced G2 DNA damage checkpoint could readily be uncoupled with ATRi, leading to dephosphorylation of CDK1\(^{\text{Tyr15}}\) and precocious mitotic entry (Fig 2). Although the mechanistic basis of the relatively weak cytotoxicity of ATRi compare to CHK1i/WEE1i remains to be defined, our observations suggest that targeting different components of the ATR–CHK1–WEE1 pathway may not be equally effective in the same cell system.
We observed that instead of reducing proliferation, low concentrations of CHK1i and WEE1i actually increased cell number (Fig 3 and S3). These data indicated that the disruption of cell cycle control after partial inhibition of CHK1/WEE1 did not necessary result in lethal mitotic catastrophe. Although the increase in cell growth occurred in a narrow concentration range of CHK1i/WEE1i and is probably cell-type dependent, this has broad clinical implications on the use of small-molecule inhibitors of the ATR–CHK1–WEE1 pathway. This is likely to be caused by the shortening of the cell cycle in the cancer cells after treatment with low concentrations of the inhibitors (Fig 4). As cancer cells including H1299 and HeLa are already highly aneuploid, they are likely to be relatively tolerant to some degree of DNA damage or chromosomal instability associated with the acceleration of cell cycle caused by partial inhibition of WEE1 pathway.

Given the potential detrimental effects of partial inhibition of the ATR–CHK1–WEE1 pathway, it is important to understand how the balance can be offset towards mitotic catastrophe. We demonstrated that one possible solution of this problem is by targeting more than one components of the pathway together. Although ATRi was not effective on its own, it could enhance the mitotic catastrophe induced by sublethal concentrations of CHK1i and WEE1i (Fig 5). Furthermore, challenging cells with CHK1i and WEE1i together induced more extensive mitotic catastrophe than the individual drugs alone (Fig 6). These results are consistent with the synergistic effects of inhibitors of CHK1 and WEE1 observed in other cancer models. For example, WEE1i (MK-1775) cooperates with the CHK1 inhibitor AR458323 in inhibiting cell proliferation in prostate and lung cancer cell lines [26]. Another CHK1 inhibitor PF-00477736 acts synergistically with WEE1i in a panel of cancer cell lines (including breast, colon, ovarian, and prostate) [27]. The CHK1 inhibitor MK-8776 also cooperates with WEE1i in reducing tumor growth in colorectal, ovarian [28], and neuroblastoma [29] mouse xenograft models. Together, these data indicated that although CHK1i/WEE1i have the potential drawback of enhancing cancer cell growth at low concentrations, targeting more than one component of the checkpoint pathway together can help to tip the balance towards mitotic catastrophe.

MATERIALS AND METHODS

DNA constructs

Plasmid expressing iRFP [30] was obtained from Addgene (Cambridge, MA, USA). Plasmid expressing iFP1.4 [31] was a gift from Roger Tsien (University of California, San Diego). Histone H2B-GFP construct was a gift from Tim Hunt (Cancer Research UK). WEE1, WEE1(K328R), WEE1NA214, and WEE1NA214(K328R) in pSLX-CMV were generous gifts from Nobumoto Watanabe (RIKEN, Japan). WEE1 cDNA was amplified using primers 5'-CGCCATGGGCTTCTCGAGCCGCACAGC-3' and 5'-TCATCGAGTATAGTAAAGGCTGA-3'. The PCR product was cut with Nco I-Xho I and ligated into pGEX-KG to create GST-WEE1 in pGEX-KG. The Nco I-Hind III fragment from GST-WEE1 in pGEX-KG was put into pUHD-P3 [32] to generate FLAG-WEE1 in pUHD-P3.

Cell culture

H1299 (non-small cell lung carcinoma) and HeLa (cervical carcinoma) were obtained from the American Type Culture Collection (Manassas, VA, USA). The HeLa used in this study was a clone that expressed the tTA tetracycline repressor chimera [33]. The nasopharyngeal carcinoma cell line HONE1 [34] was obtained from NPC AoE Cell Line Repository (The University of Hong Kong). Cells were propagated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) calf serum (Life Technologies, Carlsbad, CA, USA) (for H1299) or 10% (v/v) fetal bovine serum (for other cell lines) and 50 µM penicillin-streptomycin (Life Technologies).

HeLa cells stably expressing histone H2B-GFP [35] were used for live-cell imaging. H1299, HeLa, and HONE1 cells expressing iRFP were generated by transfection followed by cell sorting. The cells were transfected with an iRFP-expressing construct and the iRFP-positive cells were enriched by sorting using a flow cytometer with a 633-nm red laser for excitation (FACSARia II, Becton Dickinson, Franklin Lakes, NJ, USA). The cells were sorted again after one week. Three rounds of sorting were performed.

Cell lines expressing recombinant WEE1 were produced by transfecting constructs of pSLX-CMV expressing WEE1, WEE1NA214, WEE1(K328R), or WEE1NA214(K328R) into H1299 cells. The cells were then selected in medium supplemented with 100 µg/ml of G418. Medium containing G418 was replenished every three days and individual colonies were isolated and expanded in culture after about 3 weeks of selection. Cell-free extracts were prepared and the expression of WEE1 or mutants was analyzed by immunoblotting. After the establishment of the cell lines, subsequent experiments were performed in the absence of G418. Cell growth of WEE1-expressing cells was measured by plating the cells at a density of about 10,000 cells/60-mm plate, and counting the attached cells in the same randomly selected areas (five 2-mm diameter circles) every 24 h using a light microscope. The positions of the circles were fixed at the bottom of the culture plate.

Unless stated otherwise, cells were treated with the following reagents at the indicated final concentration:
AZD7762 (Selleck Chemicals), MK-1775 (Selleck Chemicals), nocodazole (Sigma-Aldrich, St. Louis, MO, USA; 0.1 µg/ml), thymidine (Sigma-Aldrich; 2 mM), and VE-821 (Selleck Chemicals; 2.5 µM). Double thymidine synchronization [36], trypan blue analysis [37] and preparation of cell-free extracts [38] were performed as previously described.

RNA interference

Unless stated otherwise, cells were transfected with siRNA (1.25 nM) using Lipofectamine RNAiMAX (Life Technologies). Stealth siRNA targeting CHK1 (GGCUUGGCAACAGUAUUUCGUUA) and WEE1 (CCUCAGGACAGUGUCGUAGAAA) were obtained from Life Technologies.

Flow cytometry

Flow cytometry analysis after propidium iodide staining was performed as described previously [37].

Infrared imaging

Infrared images of cells expressing iRFP were acquired and quantified with an Odyssey CLx system (LI-COR Biosciences, Lincoln, NE, USA).

Live-cell imaging

Cells were seeded onto 24-well culture plates and imaged using a Ti-E inverted fluorescent microscope (Nikon, Tokyo, Japan) equipped with a SPOT BOOST EMCCD camera (Diagnostic Instrument, Sterling Heights, MI, USA) and a INU-NI-F1 temperature, humidity, and CO₂ control system (Tokai Hit, Shizuoka, Japan). Data acquisition was carried out at 5 min/frame.

Antibodies and immunological methods

Antibodies against CDK1 [39] and cyclin B1 [35] were obtained from sources as described previously. Antibodies against β-actin (Sigma-Aldrich), γH2AX (Bethyl Laboratories, Montgomery, TX, USA), CHK1, phospho-histone H3Ser10, and WEE1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), phospho-CDK1Thr15 and cleaved PARP1(Asp214) (BD Biosciences, Franklin Lakes, NJ, USA) were obtained from the indicated suppliers. Immunoblotting was performed as described previously [38].

Statistical Analysis

Statistical analyses were performed, and graphs were generated using Excel (Microsoft).

ACKNOWLEDGEMENTS

We thank Talha Arooz, Anita Lau, Nelson Lee, and Wai Yi Siu for technical assistance. This work was supported in part by the Research Grants Council grants 662213 and AOE-MG/M-08/06 to R.Y.C.P.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Ma, HT, Poon, RY. How protein kinases co-ordinate mitosis in animal cells. Biochem J 2011; 435:17-31.
2. Parker, LL, Piwnica-Worms, H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992; 257:1955-7.
3. Booher, RN, Holman, PS, Fattaey, A. Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity. J Biol Chem 1997; 272:22300-6.
4. Liu, F, Stanton, JJ, Wu, Z, Piwnica-Worms, H. The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol Cell Biol 1997; 17:571-83.
5. Chow, JP, Poon, RY. The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery. Oncogene 2013; 32:4778-88.
6. Chen, Y, Poon, RY. The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability. Front Biosci 2008; 13:5016-29.
7. Rothblum-Oviatt, CJ, Ryan, CE, Piwnica-Worms, H. 14-3-3 binding regulates catalytic activity of human WEE1 kinase. Cell Growth Differ 2001; 12:581-9.
8. Lee, J, Kumagai, A, Dunphy, WG. Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. Mol Biol Cell 2001; 12:551-63.
9. Smith, J, Tho, LM, Xu, N, Gillespie, DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010; 108:73-112.
10. Chow, JPH, Poon, RYC. Mitotic catastrophe. In: Enders, G, ed(s). Cell Cycle Deregulation in Cancer. New York:Springer, 2010:79-96.
11. Friedel, AM, Pike, BL, Gasser, SM. ATR/Mec1: coordinating fork stability and repair. Curr Opin Cell Biol 2009; 21:237-44.
12. Brown, EJ, Baltimore, D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality.
13. de Klein, A, Muijtjens, M, van Os, R, Verhoeven, Y, Smit, B, Carr, AM, Lehmann, AR, Hoeijmakers, JH. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr Biol 2000; 10:479-82.

14. Liu, Q, Gunetuku, S, Cui, XS, Matsuoka, S, Cortez, D, Tamai, K, Luo, G, Carattini-Rivera, S, DeMayo, F, Bradley, A, Donehower, LA, Elledge, SJ. Chk1 is an essential kinase that is regulated by Atm and required for the G2/M DNA damage checkpoint. Genes Dev 2000; 14:1448-59.

15. Tominaga, Y, Li, C, Wang, RH, Deng, CX. Murine Weel plays a critical role in cell cycle regulation and pre-implantation stages of embryonic development. Int J Biol Sci 2006; 2:161-70.

16. Sorensen, CS, Syljuasen, RG. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res 2012; 40:477-86.

17. Jones, RM, Petermann, E. Replication fork dynamics and the DNA damage response. Biochem J 2012; 443:13-26.

18. Beck, H, Naehse-Kumpf, V, Larsen, MS, O’Hanlon, KA, Patzke, S, Holmborg, C, Meljvang, J, Groth, A, Nielsen, O, Syljuasen, RG, Sorensen, CS. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol Cell Biol 2012; 32:4226-36.

19. Hirai, H, Iwasawa, Y, Okada, M, Arai, T, Nishibata, T, Kobayashi, M, Kimura, T, Kaneko, N, Ohtani, J, Yamanaka, K, Itadani, H, Takahashi-Suzuki, I, Fukuasawa, K, Oki, H, Nambu, T, Jiang, J, Sakai, T, Arakawa, H, Sakamoto, T, Sagara, T, Yoshizumi, T, Mizura, S, Kotani, H. Small-molecule inhibition of Weel kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009; 8:2992-3000.

20. Zabudoff, SD, Deng, C, Grondine, MR, Sheehy, AM, Ashwell, S, Caleb, BL, Green, S, Haye, HR, Horn, CL, Janetka, JW, Liu, D, Mouchet, E, Ready, S, Rosenhal, JL, Queva, C, Schwartz, GK, Taylor, KJ, Tse, AN, Walker, GE, White, AM. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7:2955-66.

21. Charrier, JD, Durrant, SJ, Golec, JM, Kay, DP, Knecht, RM, MacCormick, S, Mortimore, M, O’Donnell, ME, Pinder, JL, Reaper, PM, Rutherford, AP, Wang, PS, Young, SC, Pollard, JR. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J Med Chem 2011; 54:2320-30.

22. Ma, HT, Erdal, S, Huang, S, Poon, RY. Synergism between inhibitors of Aurora A and KIF11 overcomes KIF15-dependent drug resistance. Molecular Oncology 2014; in press

23. Reaper, PM, Griffiths, MR, Long, JM, Charrier, JD, MacCormick, S, Charlton, PA, Golec, JM, Pollard, JR. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 2011; 7:428-30.

24. McNeely, S, Beckmann, R, Bence Lin, AK. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol Ther 2014; 142:1-10.

25. Vriend, LE, De Witt Hamer, PC, Van Noorden, CJ, Wurdinger, T. WEE1 inhibition and genomic instability in cancer. Biochim Biophys Acta 2013; 1836:227-35.

26. Davies, KD, Cable, PL, Garrus, JE, Sullivan, FX, von Carlowitz, I, Huerou, YL, Wallace, E, Woesnner, RD, Gross, S. Chk1 inhibition and Weel1 inhibition combine synergistically to impede cellular proliferation. Cancer Biol Ther 2011; 12:788-96.

27. Carrassa, L, Chila, R, Lupi, M, Ricci, F, Celenza, C, Mazzuottoni, M, Broginni, M, Damia, G. Combined inhibition of Chk1 and Weel: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle 2012; 11:2507-17.

28. Guertin, AD, Martin, MM, Roberts, B, Hurd, M, Qu, X, Misellis, NR, Liu, Y, Li, J, Feldman, I, Benita, Y, Bloecher, A, Toniatti, C, Shumway, SD. Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition. Cancer Cell Int 2012; 12:45.

29. Russell, MR, Levin, K, Rader, J, Belcastro, L, Li, Y, Martinez, D, Pawel, B, Shumway, SD, Maris, JM, Cole, KA. Combination therapy targeting the Chk1 and Weel1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res 2013; 73:776-84.

30. Filonov, GS, Piatkevich, KD, Ting, LM, Zhang, J, Kim, K, Verkhsusa, VV. Bright and stable near-infrared fluorescent protein for in vivo imaging. Nat Biotechnol 2011; 29:575-61.

31. Shu, X, Royant, A, Lin, MZ, Aguilera, TA, Lev-Ram, V, Steinbach, PA, Tsien, RY. Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome. Science 2009; 324:804-7.

32. Ma, HT, Tsang, YH, Marxer, M, Poon, RY. Cyclin A2-cyclin-dependent kinase 2 cooperates with the PLK1-SCFbeta-TrCP1-EMI1-anaphase-promoting complex/cyclosome axis to promote genome reduplication in the absence of mitosis. Mol Cell Biol 2009; 29:6500-14.

33. Yam, CH, Sui, WY, Lau, A, Poon, RY. Degradation of cyclin A does not require its phosphorylation by CDC2 and cyclin-dependent kinase 2. J Biol Chem 2000; 275:3158-67.

34. Glaser, R, Zhang, HY, Yao, KT, Zhu, HC, Wang, FX, Li, Y, Wen, DS, Li, YP. Two epithelial tumor cell lines (HONE-1 and HONE-2) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci U S A 1989; 86:9234-8.

35. Chan, YW, Ma, HT, Wong, W, Ho, CC, On, KF, Poon, RY. CDK1 inhibitors antagonize the immediate apoptosis triggered by spindle disruption but promote apoptosis following the subsequent reduplication and abnormal
mitosis. Cell Cycle 2008; 7:1449-61.

36. Chow, JP, Poon, RY, Ma, HT. Inhibitory phosphorylation of cyclin-dependent kinase 1 as a compensatory mechanism for mitosis exit. Mol Cell Biol 2011; 31:1478-91.

37. Siu, WY, Arooz, T, Poon, RY. Differential responses of proliferating versus quiescent cells to adriamycin. Exp Cell Res 1999; 250:131-41.

38. Poon, RY, Toyoshima, H, Hunter, T. Redistribution of the CDK inhibitor p27 between different cyclin.CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol Biol Cell 1995; 6:1197-213.

39. Siu, WY, Lau, A, Arooz, T, Chow, JP, Ho, HT, Poon, RY. Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms. Mol Cancer Ther 2004; 3:621-32.